Annals of the Rheumatic Diseases

THU0384 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS PATIENTS: RESULTS FROM THE COAST-X TRIAL AT 52 WEEKS.

Annals of the Rheumatic Diseases

A. Deodhar, P. J. Mease, L. S. Gensler, P. Rahman, V. Navarro-Compán, H. Marzo-Ortega, T. Hunter, D. Sandoval, A. Kronbergs, B. Zhu, A. Leung, V. Strand

OP0106 SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY.

Annals of the Rheumatic Diseases

J. Braun, R. Blanco, E. Dokoupilova, L. S. Gensler, A. Kivitz, S. Hall, H. Kameda, D. Poddubnyy, M. Van de Sande, D. Van der Heijde, A. Wiksten, B. Porter, H. Richards, S. Haemmerle, A. Deodhar

OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY.

Annals of the Rheumatic Diseases

D. Van der Heijde, L. S. Gensler, A. Deodhar, X. Baraliakos, D. Poddubnyy, A. Kivitz, M. K. Farmer, D. Baeten, N. Goldammer, J. Coarse, M. Oortgiesen, M. Dougados

OP0103 DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?.

Annals of the Rheumatic Diseases

R. B. M. Landewé, D. Van der Heijde, M. Dougados, X. Baraliakos, F. Van den Bosch, K. Gaffney, L. Bauer, B. Hoepken, N. De Peyrecave, K. Thomas, L. S. Gensler

OP0060 MACHINE LEARNING BASED BERLIN SCORING OF MAGNETIC RESONANCE IMAGES OF THE SPINE IN PATIENTS WITH ANKYLOSING SPONDYLITIS FROM THE MEASURE 1 STUDY.

Annals of the Rheumatic Diseases

A. Jamaludin, R. Windsor, S. Ather, T. Kadir, A. Zisserman, J. Braun, L. S. Gensler, P. Machado, M. ?stergaard, D. Poddubnyy, T. Coroller, B. Porter, S. Mpofu, A. Readie

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.

Annals of the Rheumatic Diseases

Landewé RB, van der Heijde D, Dougados M, Baraliakos X, Van den Bosch FE, Gaffney K, Bauer L, Hoepken B, Davies OR, de Peyrecave N, Thomas K, Gensler LS

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.

Annals of the Rheumatic Diseases

van der Heijde D, Gensler LS, Deodhar A, Baraliakos X, Poddubnyy D, Kivitz A, Farmer MK, Baeten D, Goldammer N, Coarse J, Oortgiesen M, Dougados M

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).

Annals of the Rheumatic Diseases

Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS, COAST-V and COAST-W Study Groups

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.

Annals of the Rheumatic Diseases

Boel A, Molto A, van der Heijde D, Ciurea A, Dougados M, Gensler LS, Santos MJ, De Miguel E, Poddubnyy D, Rudwaleit M, van Tubergen A, van Gaalen FA, Ramiro S

Development and validation of risk stratification trees for incident slow gait speed in persons at high risk for knee osteoarthritis.

Annals of the Rheumatic Diseases

Sharma L, Kwoh K, Lee JJ, Cauley J, Jackson R, Hochberg M, Chang AH, Eaton C, Nevitt M, Song J, Almagor O, Chmiel JS

Pages